Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06534411 · ClinicalTrials.gov registry record · Phase 3
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
A Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 1,023
- Enrollment target
- 20
- Study locations
NCT06534411 is a Phase 3 study of Diabetes Mellitus, Type 2 that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 1,023 participants, below the 4,482-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT06534411, a Phase 3 study of Diabetes Mellitus, Type 2, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,023 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.
Conditions Studied
Interventions
- DRUG Tirzepatide
- DRUG Semaglutide
- DRUG Cagrilintide
Study Locations (20)
California
- Velocity Clin Res-Chula Vista - Chula Vista
- John Muir Physicians Network - Concord
- Diabetes & Endocrine Specialists - La Mesa - La Mesa
- Velocity Clin Research LA - Los Angeles
- Desert Oasis Healthcare - Palm Springs
- Velocity Clin Res Santa Ana - Santa Ana
- Velocity Clin Res - Panorama - Van Nuys
Florida
- Tampa Bay Medical Research - Clearwater
- AGA Clinical Trial - Hialeah
- Clinical Trial Services Corp - Miami
- Bioclinical Research Alliance - Miami
- New Horizon Research Center - Miami
- South Broward Research LLC - Miramar
- West Orange Endocrinology - Ocoee
Arizona
- Velocity Clinical Research-Phoenix - Phoenix
- AES Tucson DRS - Tucson
Alabama
- Cahaba Research - Pelham
Arkansas
- Woodland Int. Research Group - Little Rock
Colorado
- Optumcare Clinical Trials,LLC-Golden - Colorado Springs
District of Columbia
- FEME Medical LLC - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,023 participants |
| Start Date | 2024-11-05 |
| Est. Completion | 2026-07-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06534411
The ClinicalTrials.gov registry entry for NCT06534411 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,023 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,482-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (77% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 3 interventions - of which Tirzepatide is the first listed.
NCT06534411 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06534411 about?
NCT06534411 is a clinical study titled "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both". This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some co...
What is the current status of trial NCT06534411?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,023 participants. The study started on 2024-11-05. Estimated completion is 2026-07-14.
What conditions does trial NCT06534411 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT06534411?
The interventions under investigation include: Tirzepatide (DRUG), Semaglutide (DRUG), Cagrilintide (DRUG).
Who is sponsoring clinical trial NCT06534411?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06534411 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
-
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.